factual

Five-year GBM survival rises from 5% to 13%

In the pivotal glioblastoma trial, the control group receiving radiation plus temozolomide had about 5 percent five-year survival, while adding Tumor Treating Fields raised five-year survival to about 13 percent, with survival curves separating at every point.

factualpending

Speaker

Bill

Evidence Quote

“we increased the five year survival from 5% to about 13%”

Source

Novocure: Using Physics to Fight Cancer— Business Breakdowns
Created: 11/19/2026, 2:27:17 AM

Your notes

Loading notes...